Holen Sie sich die Stockscreener-App
219.94
1.20%
-2.68
Handel nachbörslich:
219.94
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$222.62
Offen:
$221.74
24-Stunden-Volumen:
542.29K
Relative Volume:
0.62
Marktkapitalisierung:
$32.31B
Einnahmen:
$4.93B
Nettoeinkommen (Verlust:
$1.25B
KGV:
25.97
EPS:
8.47
Netto-Cashflow:
$1.38B
1W Leistung:
+0.11%
1M Leistung:
-4.90%
6M Leistung:
-7.97%
1J Leistung:
+11.06%
1-Tages-Spanne:
$219.70
$223.14
1-Wochen-Bereich:
$219.56
$227.00
52-Wochen-Spanne:
$172.19
$263.05
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
219.94 | 32.31B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
491.84 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.50 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
95.77 | 47.37B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BAX
Baxter International Inc
|
33.75 | 17.31B | 17.28B | 108.00M | 391.00M | 0.20 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well” - Insider Monkey
ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 72% - Simply Wall St
Solid sales from ASX healthcare leader - Morningstar.com.au
Is ResMed Stock Outperforming the Dow? - Nasdaq
ResMed initiated with an Overweight at Morgan Stanley - Yahoo Finance
Is ResMed Stock Outperforming The Dow? - Barchart
Resmed Says CPAP Therapy Reduces Risk Of Death By 37% In Sleep Apnea Patients - Nasdaq
Resmed’s Brand Evolution - Sleep Review
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Why Breville, Flight Centre, Orica, and ResMed shares are dropping today - MSN
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare And Medtronic - Barchart
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic - Yahoo Finance
Why APA, Aurelia Metals, Magnetic Resources, and ResMed shares are rising today - MSN
ResMed’s chief commercial officer sells $2.33 million in stock By Investing.com - Investing.com Australia
Should you buy this top ASX share in the dip? - MSN
Resmed to Consolidate Portfolio into One Brand; Shares Fall 5% -March 12, 2025 at 12:33 am EDT - Marketscreener.com
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $230,360 in company stock By Investing.com - Investing.com South Africa
ResMed CFO Brett Sandercock sells $230,360 in company stock - Investing.com India
Resmed Chief Commercial Officer Offloads $2.3 Million Worth of Shares -March 11, 2025 at 06:27 pm EDT - Marketscreener.com
Resmed Inc Announces Proposed Sale of Securities - TipRanks
ResMed Inc. CEO Reports Stock Transactions Under Rule 10b5-1 Plan - TipRanks
ResMed’s chief commercial officer sells $2.33 million in stock - Investing.com
Resmed unveils unified brand to streamline services - Mass Device
ResMed CEO Michael J. Farrell sells $1.84 million in stock - Investing.com India
Resmed Unveils Unified Brand To Lead The Global Sleep And Health Technology Revolution - Marketscreener.com
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution - The Korea Bizwire
Resmed Consolidating Brands, Product Lines Under Single Name -March 11, 2025 at 09:25 am EDT - Marketscreener.com
Resmed Unveils Comprehensive Brand Evolution to Enhance Global Sleep and Breathing Health Engagement - Nasdaq
Respiratory Inhalers Market to Witness Remarkable Growth with ResMed Inc., Fisher & Paykel Healthcare, Medtronic - openPR
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD) - Yahoo Finance
ResMed Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Jones Financial Companies Lllp Grows Stock Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Brokers rate these 2 ASX growth stocks as top buys - MSN
ResMed Inc Officer Plans Sale of Common Shares - TipRanks
ResMed Among Top Stocks For Recent And Long-Term Profit Growth - Investor's Business Daily
ResMed Insiders Sold US$12m Of Shares Suggesting Hesitancy - Simply Wall St
ResMed (NYSE:RMD) Cut to “Hold” at StockNews.com - Defense World
Citi slaps buy rating on ResMed shares - MSN
Is it Worth Adding ResMed Stock to Your Portfolio Now? - MSN
ResMed (NYSE:RMD) Raised to “Buy” at Citigroup - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - Defense World
Europe Sleep Apnea Devices Analysis Report 2025: Market Set - GlobeNewswire
Europe Sleep Apnea Devices Analysis Report 2025: Market Set for Notable Growth, Reaching $3.77 Billion by 2033 with Natus Medical, ResMed, and Koninklijke Philips Leading - Yahoo Finance
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):